Page 16 - January 2021 South Florida Hospital News
P. 16

ONCOLOGY UPDATE in South Florida


                                                                                    Liquid Biopsies: Endless Possibilities


                                                                                            on Cancer’s New Frontier
                   We congratulate our

                                                                                    For more than 40 years,                       This approach, available in
                    colleagues on their
                                                                                  oncologists  prescribed                       several platforms, is commer-
                                                                                  “empiric” chemotherapy                        cially viable for cancer care
                                                                                  for cancer patients, using                    and recently approved for
                          appointments
                                                                                  their  experience  and                        reimbursement   by    the
                                                                                  instincts to search for the                   Centers for Medicaid and
                                                                                  right combination of drugs                    Medicare Services (CMS). At
                          Jorge Galvez Silva, M.D.,                               to kill or, at least, prevent                 the    Memorial   Cancer
                                                                                  further multiplication of                     Institute (www.mhs.net/ser-
                                  Director, and                                   cancer cells. This was the                    vices/cancer), we’re having
                           Ossama M. Maher, M.D.,                                 norm given the absence of                     success using liquid biopsies
                                                                                  a more precise understand-  BY LUIS E. RAEZ, MD,   to diagnose and evaluate new
                          Associate Director of the                               ing of the specific makeup   FACP, FCCP       cancer patients, especially
                                                                                  of tumors.                                    those with lung cancer, where
                Blood & Bone Marrow Transplant Center                                                                           we’ve identified nine genes
                                                                                  The Present                         that are known to cause the disease. We
                      at Nicklaus Children’s Hospital.                              Today, thanks to genetic analysis of   have targeted treatments for each and can
                                                                                  tumors, we’re able to identify the genes   personalize therapy per patient.
                                                                                  responsible for the oncogenesis and spread   Maria, a 41-year-old stage IV lung can-
                                                                                  of a tumor and can be more targeted in our   cer patient, is someone who recently ben-
                        K K          I I               Z Z                        through next generation sequencing   no warning signs for lung cancer, she, like
                                                                                                                      efited from this technology. Since there are
                                                                                  treatment. Until now, what we learned
                                                                                                                      60% of the lung cancer patients we see,
                                                                                  (NGS, a survey of the genome in search of
                                                                                  anomalies), the most widely used technol-
                                                                                                                      presented to us at a later stage. Her liquid
                                                                                  ogy, was sometimes hampered by not hav-
                                                                                  ing enough tumor tissue required to per-  biopsy uncovered an ALK fusion, which
                                                                                                                      told us the best treatment for her cancer
                                                                                  form the genetic analysis. Additionally,   would be to receive an oral agent, which
                               Medical                                            with tumors being heterogeneous, differ-  was successful, instead of palliative and
                                                                                                                      empiric chemotherapy. She responded
                                                                                  ent areas of a suspicious solid mass could
                                                                                  contain more cancer cells than others,
                                                                                  even within the same sample or when   well to targeted therapy, didn’t need fur-
                                                                                                                      ther chemotherapy, and said, “I’m still
                      5955 Ponce de Leon Blvd., Coral Gables, FL 33146            comparing several samples from the same   young, have a wonderful family, a wonder-
                                                                                  patient.                            ful life, and am confident the research is
                                                                                                                      going to give me many more years."
                                                                                  A Better Way
                                                                                    Tumors release DNA into the blood-  What’s Next?
                                                                                  stream that can be collected via a blood   The possibilities with liquid biopsies are
                                                         e
                                o
             T h  e A  nd  e  rson F    a     l i m  y C a nc r I        e t u t i t s n  test, separated from the plasma, and stud-  endless. In the future, we are hopeful they
                                                                                  ied. The circulating tumor DNA (ctDNA)   can be used to predict recurrences of can-
                                                                                  and intact circulating tumor cells (CTCs)   cer in patients who have had surgery.
                                                                                  are two of the targeted components during   Taking its potential a step further, it’s pos-
                                                                                  what is known as a “liquid biopsy.”    sible we could diagnose cancer through
                                                                                    While we’ve been able to extract DNA   blood testing that would identify DNA
                                                                                  from identified tumor cells and study its   alterations. This early-stage diagnosis
                                                                                  molecular makeup since the 1980s, we   could happen even before the patient
                                                                                  haven’t been able to combine that with   experiences symptoms or gets radiology
                                                                                  NGS until now. This is a quantum leap in   findings. It wouldn’t be surprising if liquid
                                                                                  our field, resulting in the delivery of criti-  biopsies completely replace tissue biopsy
                                                                                  cal information within two weeks (as   at some point in the not-too-distant
                                                                                  opposed to the four or five required for tis-  future.
             A t J u  e t i p  r M e  a c i d  l C e  r e t n r w e t  k a  e a m  r a n i l p i c s i d i t l u  y a p  r p ao  c h t                         sue analysis) that isn’t affected by tumor
             C   e c n a  r p  e i t a  t n  s h ave a  e c c s e  s t o s o m e o f t h e m  s o  t r e n o w n ed p  s y h                         heterogeneity.    Dr. Luis Raez is chief scientific officer and
              h t  e fi  l e  d a n d t h e m  s o  t a dv v na  e c  d t  h c e  n  o l o  g y i n t h e r e  o i g  n .  uO  r e x  l                         The offshoot of all this is that we can   medical director at the Memorial Cancer
              y t  p  s e   of  a c f   nc er   i ,  nc l udi ng omc  x e l p   a nd  ad  a v  nc e d  s t ag  , s e   w htiw   s p
             i n b  t s a e r  , l u n g , g  n y  o l o c e  g , gci g  l a n i t s e t n i o r t s a  , p  c i t a e r c n a  , a d ln  i ve                         now use liquid biopsies and NGS to eval-  Institute, part of the Hollywood-based
                                                                                  uate patients at several different points of   Memorial Health Care System. He is board
             A t t h e A n d  o s r e  n F a m  l i  y C na  e c  r I  e t u t i t s n  , yo  l u’  l h ave t h e f e l oe  f a                         their cancer treatment, making adjust-  certified in internal medicine and medical
             h    a t i p s o  l b  e k c a  d by t h e e x ep  s i t r  e a n d t  h c e  n  o l o  g y r  n i l a v i  g t a to f                         ments in their chemotherapy based on   oncology and board eligible in hematology. Dr.
                                                         h
                       er i
             mm ee di  c l a c  c l a  en ter  inc ludi ng: :                       new anomalies we discover. A more pre-  Raez is active in cancer research and also
                         ncl
                dic
                     ent
                            uding

             •  yC  be rk  e f i n  ®  M6 ™      •   nO•                   c ol o gy y a  cise style of medicine, it enables us to   clinical professor of medicine at Florida




                •
                                                           P
                                                                                  develop targeted agents to kill specific can-  International University’s Herbert Wertheim
                                                 •
             • nI  r t  ao p er  e v i t a   E  r t c e l  on adiR  i t a  on  • iR  k s   A  e s s s s
             •
               T her a p                        y  Co u  n i l e s n  n           cer tumors with drugs proven to be effec-  College of Medicine. He currently serves as
                                                                                  tive, curing some patients and potentially   president of the Florida Society of Clinical
             •  arV                   •   i an  T  u r  e Be am  n i  L  e ar cA  r o t a r e l e c  •  nO•                      l o c  og
                                                                                  improving the quality of life for all.                 Oncology (FLASCO).
             •  iM  i n  m  l l a  y I  i s a v n  ve a n d R boR  i t o  c S  g r u  y r e  •   nO•                   o c  lo



                •


                •




             •  hemC  t o  her a p y  a nd  I  s u f n s i on  Ser  s e c i v  • Cl•  n i

             F or  m or e  in f or m at i on  a bo  otuo  r u   p r og ra m s  a n
              u j  r e t i p  m e  c . d  o m  o /  c n  o l o  g  o r  c  l l a   5 6 1 -2 6 3
                                 y

                                                           This  iss


                                                              i
                                                             h
                                                           T
                                                               s



                                                                 i




                                                           W
                                                           Where  ereh

                                                           You  Want tnaWauo
                                                           Y
                          • •                              Yo         W






                                                           T                       .
                                                           To
                                                           To  Be. eBo
         16                        January 2021                                                           southfloridahospitalnews.com                                                                       South Florida Hospital News
   11   12   13   14   15   16   17   18   19   20   21